Premium
Intravenous Immunoglobulins in Autoimmune and Inflammatory Diseases
Author(s) -
SIBÉRIL SOPHIE,
ELLURU SRIRAMULU,
GRAFFDUBOIS STÉPHANIE,
NEGI VIRSINGH,
DELIGNAT SANDRINE,
MOUTHON LUC,
LACROIXDESMAZES SÉBASTIEN,
KAZATCHKINE MICHEL D.,
BAYARY JAGADEESH,
KAVERI SRINI V.
Publication year - 2007
Publication title -
annals of the new york academy of sciences
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.712
H-Index - 248
eISSN - 1749-6632
pISSN - 0077-8923
DOI - 10.1196/annals.1423.052
Subject(s) - immunology , immune system , antibody , economic shortage , effector , intravenous immunoglobulins , medicine , receptor , complement receptor , complement system , linguistics , philosophy , government (linguistics)
: Initially used for the treatment of immunodeficiencies, intravenous immunoglobulins (IVIg) have increasingly been used as immunomodulatory agents in autoimmune and inflammatory disorders. The mode of action of IVIg is enigmatic, probably involving Fc‐dependent and/or F(ab′)2‐dependent nonexclusive mechanisms of action. IVIg broadly interacts with the different components of the immune system: cytokines, complement, Fc receptors, and several cell surface immunocompetent molecules. IVIg has also an impact on effector functions of immune cells. These mechanisms of action of IVIg reflect the importance of natural antibodies in the maintenance of immune homeostasis. We discuss here the recent advances in the understanding of immunoregulatory effects of IVIg, and we pointed out the need for new strategies to overcome the predicted increasing worldwide shortage of IVIg.